Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

March 22, 2016

Primary Completion Date

January 21, 2024

Study Completion Date

January 21, 2026

Conditions

Lung CancerNon-small Cell Lung Cancer

Interventions

DRUG

Vorinostat

Administered per treatment arm guidelines.

DRUG

Pembrolizumab

Administered per treatment arm guidelines.

Trial Locations (1)

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT02638090 - Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter